C. Gregory Elliott
No Rating Available
(Learn About Our Rating System)

C. Gregory Elliott, MD

Languages spoken: English

Since July of 2007, Greg Elliott, M.D., M.A.C.P., has served as Chairman of the Department of Medicine at Intermountain Medical Center. In this position he is responsible for graduate medical education, continuing medical education, research and clinical care delivered at Intermountain Medical Center by more than 250 physicians who are board certified in internal medicine or relevant specialties of internal medicine. Prior to assuming these responsibilities, Dr. Elliott served as the Chief of the Pulmonary/Critical Care and Sleep Division at LDS Hospital.

A 1969 graduate of Brown University, Dr. Elliott earned his M.D. with honors from the University of Maryland School of Medicine. He completed his residency and chief medical residency at the University of Maryland hospitals and he completed fellowship training in pulmonary and critical care medicine at the University of Utah hospitals in 1978. After brief service on the faculty of the University of Maryland Medical School, Dr. Elliott returned to the University of Utah School of Medicine in 1980.

Shortly after returning to Utah, Dr. Elliott became the principal investigator of a NIH award to study primary pulmonary hypertension. He also directed research to advance the scientific basis for diagnosis, prevention, and treatment of venous thromboembolism. Known widely as an educator….. Dr. Elliott received numerous teaching awards, including the University of Utah School of Medicine Outstanding Faculty Award (1987).

From 1997 to 2001 he served as Governor of the Utah Chapter of the American College of Physicians, and in 2003 Dr. Elliott was awarded the honor of Master of the American College of Physicians.

Dr. Elliott has pursued research opportunities throughout his career. As an investigator he has authored or co-authored more than 100 peer-reviewed publications. He maintains an active research portfolio to advance understanding of pulmonary hypertension and venous thromboembolism. He continues to review manuscripts for leading peer reviewed scientific journals and he has served on the editorial board of CHEST since 2006. He also serves as a distinguished advisor to the scientific leadership council of the Pulmonary Hypertension Association. Greg Elliott, M.D., M.A.C.P., is the Medical Director of the Pulmonary Hypertension Center at Intermountain Medical Center. This center was established in 1983 as one of a few select centers identified by the National Institutes of Health (NIH) for the diagnosis and treatment of patients with pulmonary hypertension. The center has maintained a leading edge approach to the diagnosis and treatment of pulmonary hypertension based upon collaboration with other leading centers throughout the United States and Europe. As such, the center continues to translate basic advances to patient care. Dr. Elliott’s lifetime commitment to patients and families affected by pulmonary hypertension has earned him widespread recognition, including the Pulmonary Hypertension Association’s Outstanding Physician Award.

Specialties

Board Certification

American Board of Internal Medicine (Sub: Pulmonary Disease)
American Board of Internal Medicine (Internal Medicine)

Since July of 2007, Greg Elliott, M.D., M.A.C.P., has served as Chairman of the Department of Medicine at Intermountain Medical Center. In this position he is responsible for graduate medical education, continuing medical education, research and clinical care delivered at Intermountain Medical Center by more than 250 physicians who are board certified in internal medicine or relevant specialties of internal medicine. Prior to assuming these responsibilities, Dr. Elliott served as the Chief of the Pulmonary/Critical Care and Sleep Division at LDS Hospital.

A 1969 graduate of Brown University, Dr. Elliott earned his M.D. with honors from the University of Maryland School of Medicine. He completed his residency and chief medical residency at the University of Maryland hospitals and he completed fellowship training in pulmonary and critical care medicine at the University of Utah hospitals in 1978. After brief service on the faculty of the University of Maryland Medical School, Dr. Elliott returned to the University of Utah School of Medicine in 1980.

Shortly after returning to Utah, Dr. Elliott became the principal investigator of a NIH award to study primary pulmonary hypertension. He also directed research to advance the scientific basis for diagnosis, prevention, and treatment of venous thromboembolism. Known widely as an educator….. Dr. Elliott received numerous teaching awards, including the University of Utah School of Medicine Outstanding Faculty Award (1987).

From 1997 to 2001 he served as Governor of the Utah Chapter of the American College of Physicians, and in 2003 Dr. Elliott was awarded the honor of Master of the American College of Physicians.

Dr. Elliott has pursued research opportunities throughout his career. As an investigator he has authored or co-authored more than 100 peer-reviewed publications. He maintains an active research portfolio to advance understanding of pulmonary hypertension and venous thromboembolism. He continues to review manuscripts for leading peer reviewed scientific journals and he has served on the editorial board of CHEST since 2006. He also serves as a distinguished advisor to the scientific leadership council of the Pulmonary Hypertension Association. Greg Elliott, M.D., M.A.C.P., is the Medical Director of the Pulmonary Hypertension Center at Intermountain Medical Center. This center was established in 1983 as one of a few select centers identified by the National Institutes of Health (NIH) for the diagnosis and treatment of patients with pulmonary hypertension. The center has maintained a leading edge approach to the diagnosis and treatment of pulmonary hypertension based upon collaboration with other leading centers throughout the United States and Europe. As such, the center continues to translate basic advances to patient care. Dr. Elliott’s lifetime commitment to patients and families affected by pulmonary hypertension has earned him widespread recognition, including the Pulmonary Hypertension Association’s Outstanding Physician Award.

Board Certification and Academic Information

Academic Departments Internal Medicine -Professor
Academic Divisions Public Health
Board Certification
American Board of Internal Medicine (Sub: Pulmonary Disease)
American Board of Internal Medicine (Internal Medicine)

Education history

Undergraduate Biology - Brown University B.A.
Professional Medical Medicine - University of Maryland M.D.
Internship University of Maryland Intern
Residency Internal Medicine - University of Maryland Resident
Fellowship University of Utah School of Medicine Fellow
Chief Resident University of Maryland Chief Resident

Selected Publications

Journal Article

  1. Adams DM, Stevens SM, Woller SC, Evans RS, Lloyd JF, Snow GL, Allen TL, Bledsoe JR, Brown LM, Blagev DP, Lovelace TD, Shill TL, Conner KE, Aston VT, Elliott C (2013). Adherence to PIOPED II investigators' recommendations for computed tomography pulmonary angiography. The American journal of medicine, 126(1), 36-42.
  2. Best DH, Austin ED, Chung WK, Elliott C (2014). Genetics of pulmonary hypertension. Current opinion in cardiology, 29(6), 520-7.
  3. Willoughby L, Adams DM, Evans RS, Lloyd JF, Stevens SM, Woller SC, Bledsoe JR, Aston VT, Wilson EL, Elliott C (2018). Preemptive Anticoagulation in Patients With a High Pretest Probability of Pulmonary Embolism: Are Guidelines Followed?. Chest, 153(5), 1153-1159.
  4. Desmarais J, Elliott C (2016). Familial Chronic Thromboembolic Pulmonary Hypertension. Chest, 149(4), e99-e101.
  5. Woller SC, Stevens SM, Adams DM, Evans RS, Lloyd JF, Snow GL, Bledsoe JR, Gay DZ, Patten RM, Aston VT, Elliott C (2014). Assessment of the safety and efficiency of using an age-adjusted D-dimer threshold to exclude suspected pulmonary embolism. Chest, 146(6), 1444-1451.
  6. Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW, Frost AE, Liou TG, Turner M, Feldkircher K, Miller DP, Elliott C (2011). Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest, 140(1), 19-26.
  7. Kaplan D, Casper TC, Elliott CG, Men S, Pendleton RC, Kraiss LW, Weyrich AS, Grissom CK, Zimmerman GA, Rondina M (2015). VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock. Chest, 148(5), 1224-1230.
  8. Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, Romero AJ, Benton WW, Elliott CG, McGoon MD, Benza R (2015). Five-Year outcomes of patients enrolled in the REVEAL Registry. Chest, 148(4), 1043-54.
  9. Taichman DB, Ornelas J, Chung L, Klinger JR, Lewis S, Mandel J, Palevsky HI, Rich S, Sood N, Rosenzweig EB, Trow TK, Yung R, Elliott CG, Badesch D (2014). Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest, 146(2), 449-475.
  10. Frost AE, Farber HW, Barst RJ, Miller DP, Elliott CG, McGoon M (2013). Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry. Chest, 143(1), 185-195.
  11. Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, Krichman A, Liou TG, Raskob GE, Wason P, Feldkircher K, Turner M, McGoon M (2011). The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest, 139(1), 128-37.
  12. Elliott CG, Barst RJ, Seeger W, Porres-Aguilar M, Brown LM, Zamanian RT, Rubin L (2010). Worldwide physician education and training in pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest, 137(6 Suppl), 85S-94S.
  13. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon M (2010). Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest, 137(2), 376-87.
  14. Badlam JB, Badesch DB, Austin ED, Benza RL, Chung WK, Farber HW, Feldkircher K, Frost AE, Poms AD, Lutz KA, Pauciulo MW, Yu C, Nichols WC, Elliott C (2021). United States Pulmonary Hypertension Scientific Registry Baseline Characteristics. Chest, 159(1), 311-327.
  15. Benza RL, Kanwar MK, Raina A, Scott JV, Zhao CL, Selej M, Elliott CG, Farber H (2021). Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. Chest, 159(1), 337-346.
  16. Chaisson NF, Dodson MW, Elliott C (2016). Pulmonary Capillary Hemangiomatosis and Pulmonary Veno-occlusive Disease. Clinics in chest medicine, 37(3), 523-34.
  17. Trow TK, Elliott C (2010). Venous thromboembolism. Preface. Clinics in chest medicine, 31(4), xi-xii.
  18. Sitbon O, Benza RL, Badesch DB, Barst RJ, Elliott CG, Gressin V, Lemarié JC, Miller DP, Muros-Le Rouzic E, Simonneau G, Frost AE, Farber HW, Humbert M, McGoon M (2015). Validation of two predictive models for survival in pulmonary arterial hypertension. The European respiratory journal, 46(1), 152-64.
  19. Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Lu W, Spiro TE, Barnathan ES, Raskob G (2020). Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. Journal of the American College of Cardiology, 75(25), 3140-3147.
  20. Sundar KM, Elliott CG, Thomsen G (2001). Tetracycline aspiration. Case report and review of the literature. Respiration; international review of thoracic diseases, 68(4), 416-9.
  21. Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG, Halperin J, Haskell L, Hiatt WR, Maynard GA, Peters G, Spiro T, Steg PG, Suh EY, Weitz J (2016). The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thrombosis and haemostasis, 115(6), 1240-8.
  22. Tapson VF, Carroll BA, Davidson BL, Elliott CG, Fedullo PF, Hales CA, Hull RD, Hyers TM, Leeper KV Jr, Morris TA, Moser KM, Raskob GE, Shure D, Sostman HD, Taylor Thompson (1999). The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American Thoracic Society. American journal of respiratory and critical care medicine, 160(3), 1043-66.
  23. Maron BA, Abman SH, Elliott CG, Frantz RP, Hopper RK, Horn EM, Nicolls MR, Shlobin OA, Shah SJ, Kovacs G, Olschewski H, Rosenzweig E (2021). Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. American journal of respiratory and critical care medicine, 203(12), 1472-1487.
  24. Woller SC, Stevens SM, Towner S, Olson J, Christensen P, Hamilton S, Newman L, Mott L, Hu P, Brunisholz KD, Long Y, Lloyd J, Evans RS, Cannon W, Elliott C (2015). Computerized clinical decision support improves warfarin management and decreases recurrent venous thromboembolism. Clinical and applied thrombosis/hemostasis, 21(3), 197-203.
  25. Brown SM, Elliott CG, Paine (2013). Response to open peer commentaries on "Withdrawal of nonfutile life support after attempted suicide". The American journal of bioethics, 13(3), W3-5.
  26. Brown SM, Elliott CG, Paine (2013). Withdrawal of nonfutile life support after attempted suicide. The American journal of bioethics, 13(3), 3-12.
  27. Ageno W, Lopes RD, Goldin M, Yusen RD, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard G, Steg PG, Weitz JI, Suh E, Lu W, Barnathan ES, Raskob GE, Spyropoulos A (2021). Rivaroxaban for Extended Thromboprophylaxis in Acutely Ill Medical Patients 75 Years of Age or Older. Journal of thrombosis and haemostasis, 19, 2772-2780.
  28. Elliott C (2021). Genetic Counseling and Testing in Pulmonary Arterial Hypertension. Methodist DeBakey cardiovascular journal, 17(2), 101-105.
  29. Elliott C (2013). Robyn J. Barst, MD. Pulmonary circulation, 3(4), 968.
  30. Elliott CG, Austin ED, Badesch D, Badlam J, Benza RL, Chung WK, Farber HW, Feldkircher K, Frost AE, Poms AD, Lutz KA, Pauciulo MW, Yu C, Nichols W (2019). United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications. Pulmonary circulation, 9(2), 2045894019851696.
  31. Woller SC, Stevens SM, Kaplan D, Wang TF, Branch DW, Groat D, Wilson EL, Armbruster B, Aston VT, Lloyd JF, Rondina MT, Elliott C (2021). Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood advances, 6(6), 1661-1670.
  32. Bledsoe JR, Kelly C, Stevens SM, Woller SC, Haug P, Lloyd JF, Allen TL, Butler AM, Jacobs JR, Elliott C (2021). Electronic pulmonary embolism clinical decision support and effect on yield of computerized tomographic pulmonary angiography: ePE-A pragmatic prospective cohort study. Journal of the American College of Emergency Physicians open, 2(4), e12488.
  33. Cirulis MM, Knox DB, Stoddard GJ, Brown LM, Elliott CG, Brown SM, Dodson M (2022). The CTEPH Trajectories Study: Assessment of Follow-up after Acute Pulmonary Embolism to Identify Missed Opportunities for CTEPH Diagnosis. Annals of the American Thoracic Society, 19, 1428-1432.
  34. Dodson MW, Cirulis MM, Li H, Yue Z, Brown LM, Elliott C (2022). Frequency of Thrombotic Risk Factors in Patients with Chronic Thromboembolic Pulmonary Hypertension and Acute Pulmonary Embolism: A Case-Control Study. Clinical and applied thrombosis/hemostasis, 28, 10760296211073277.
  35. Raskob GE, Ageno W, Albers G, Elliott CG, Halperin J, Maynard G, Steg PG, Weitz JI, Albanese J, Yuan Z, Levitan B, Lu W, Suh EY, Spiro T, Lipardi C, Barnathan ES, Spyropoulos A (2022). Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. Journal of the American Heart Association, 11, e026229.
  36. Spyropoulos AC, Goldin M, Ageno W, Albers GW, Elliott CG, Hiatt WR, Halperin JL, Maynard G, Steg PG, Weitz JI, Spiro TE, Lu W, Marsigliano J, Raskob GE, Barnathan E (2022). Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial. TH open, 6(3), e177-e183.
  37. Evans JD, Girerd B, Montani D, Wang XJ, Galiè N, Austin ED, Elliott G, Asano K, Grünig E, Yan Y, Jing ZC, Manes A, Palazzini M, Wheeler LA, Nakayama I, Satoh T, Eichstaedt C, Hinderhofer K, Wolf M, Rosenzweig EB, Chung WK, Soubrier F, Simonneau G, Sitbon O, Gräf S, Kaptoge S, Di Angelantonio E, Humbert M, Morrell N (2016). BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. The Lancet. Respiratory medicine, 4(2), 129-37.
  38. Scarpato BM, Locke BW, Bledsoe J, Knox DB, Conner K, Stoddard GJ, Cirulis MM, Elliott CG, Dodson M (2023). The association between pulmonary artery enlargement and mortality in an Emergency Department population undergoing computed tomography pulmonary angiography. Pulmonary circulation, 13(2), e12225.
  39. Dodson MW, Cirulis MM, Elliott C (2022). Analysis of family histories suggests shared genetic risk for chronic thromboembolic pulmonary hypertension and venous thromboembolism. Pulmonary circulation, 12(4), e12170.
  40. Morland K, Gerges C, Elwing J, Visovatti SH, Weatherald J, Gillmeyer KR, Sahay S, Mathai SC, Boucly A, Williams PG, Harikrishnan S, Minty EP, Hobohm L, Jose A, Badagliacca R, Lau EMT, Jing ZC, Vanderpool RR, Fauvel C, Leonidas Alves J Jr, Strange G, Pulido T, Qian J, Li M, Mercurio V, Zelt JGE, Moles VM, Cirulis MM, Nikkho SM, Benza RL, Elliott C (2023). Real-world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real-world Evidence Working Group. Pulmonary circulation, 13(4), e12317.
  41. Scarpato BM, McDonald J, Bayrak-Toydemir P, Elliott CG, Cahill BC, Emerson LL, Keenan L (2023). The Shunt of It. Chest, 163(5), e201-e205.

Review

  1. Elliott (1999). Thrombolytic therapy for venous thromboembolism. Current opinion in hematology, 6(5), 304-8.

Case Report

  1. Oriaku I, LeSieur MN, Nichols WC, Barrios R, Elliott CG, Frost (2020). A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype. Pulmonary circulation, 10(3), 2045894020931315.

Editorial

  1. Davidson BL, Tapson VF, Irwin RS, French CL, Elliott CG, Levi (2021). Pharyngeal Antisepsis to Reduce COVID-19 Pneumonia. The American journal of medicine, 134(3), 297-298.
  2. Elliott CG, Brown L (2009). Pulmonary embolism: another piece of the puzzle?. Chest, 136(5), 1193-1194.
  3. Elliott CG, Hill N (2020). One for the Ages. Chest, 158(3), 856-857.
  4. Austin ED, Elliott C (2020). TBX4 syndrome: a systemic disease highlighted by pulmonary arterial hypertension in its most severe form. The European respiratory journal, 55(5),

Letter

  1. Dodson MW, Sumner K, Carlsen J, Cirulis MM, Wilson EL, Gadre A, Fernandes TM, Brown LM, Best DH, Elliott C (2020). The Factor V Leiden variant and risk of chronic thromboembolic pulmonary hypertension. The European respiratory journal, 56(4),
  2. Elliott CG, Orme J Jr, Weaver L (2019). Pneumatic Compression in Venous Thromboprophylaxis. The New England journal of medicine, 381(1), 94.
  3. Ghio AJ, Crapo RO, Elliott C (1990). Survey of reference equations used to predict pulmonary function in children. Pediatric pulmonology, 8(2), 126-7.
  4. Klinger JR, Elliott G, Levine DJ, Bossone E, Duvall L, Fagan K, Frantsve-Hawley J, Kawut SM, Ryan JJ, Rosenzweig EB, Sederstrom N, Steen VD, Badesch D (2019). Response. Chest, 156(1), 187-188.

Other

  1. Kerr KM, Elliott CG, Chin K, Benza RL, Channick RN, Davis RD, He F, LaCroix A, Madani MM, McLaughlin VV, Park M, Robbins IM, Tapson VF, Terry JR, Test VJ, Jain S, Auger W (2021). Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry: Enrollment Characteristics and 1-Year Follow-up. Chest, 160(5), 1822-1831.